Answers are grounded in this paper and cite their sources.
A case report identifies chronic thrombotic microangiopathy induced by long-term imatinib therapy, suggesting potential risks of extended use.
Imatinib, a tyrosine kinase inhibitor(TKI) targeting platelet-derived growth factor receptor (PDGFR), BCR-ABL and c-KIT, is generally regarded as a well-tolerated agent. However, prolonged inhibition of PDGFR signaling can lead to endothelial dysfunction and causes thrombotic microangiopathy (TMA) in rare cases. We report a case of chronic TMA that developed after 17 years of low-dose imatinib therapy for chronic myeloid leukemia (CML), emphasizing the potential for cumulative endothelial injury associated with extended exposure.
No takes yet. Share an insight, caveat, or question.
Fujii et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: